Bill Status of HB 3256   103rd General Assembly

Short Description:  AFFORDABLE DRUG MANUFACTURING

House Sponsors
Rep. Jenn Ladisch Douglass

Last Action  View All Actions

DateChamber Action
  4/5/2024HouseRule 19(a) / Re-referred to Rules Committee

Statutes Amended In Order of Appearance
New Act
5 ILCS 140/7.5

Synopsis As Introduced
Creates the Affordable Drug Manufacturing Act. Provides that the Department of Public Health shall enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs. Requires the partnerships to result in the production or distribution of generic prescription drugs with the intent that these drugs be made widely available to public and private purchasers, providers and suppliers, and pharmacies. Provides that the Department shall comply with specified requirements when entering into partnerships or setting prices for generic prescription drugs. Requires the Department to submit separate reports to the General Assembly that: (1) assess the feasibility of directly manufacturing generic prescription drugs and selling generic prescription drugs at a fair price; and (2) describe the status of all drugs targeted under the Act and analyze how the activities of the Department may impact competition, access to targeted drugs, the costs of those drugs, and the costs of generic prescription drugs to public and private purchasers. Contains other provisions. Amends the Freedom of Information Act to exempt certain information disclosed under the Affordable Drug Manufacturing Act from inspection and copying. Contains a severability provision. Effective July 1, 2023.

 Fiscal Note (Dept. of Public Health)
 The Illinois Department of Public Health estimates a cost of $4.5 billion over a fiscal year to administer HB3256.

Actions 
DateChamber Action
  2/16/2023HouseFiled with the Clerk by Rep. Nabeela Syed
  2/17/2023HouseFirst Reading
  2/17/2023HouseReferred to Rules Committee
  2/28/2023HouseAssigned to Prescription Drug Affordability & Accessibility Committee
  3/10/2023HouseRule 19(a) / Re-referred to Rules Committee
  1/19/2024HouseChief Sponsor Changed to Rep. Jenn Ladisch Douglass
  3/5/2024HouseAssigned to Health Care Availability & Accessibility Committee
  3/20/2024HouseFiscal Note Requested by Rep. Jackie Haas
  3/26/2024HouseFiscal Note Filed
  4/5/2024HouseRule 19(a) / Re-referred to Rules Committee

Back To Top